Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Able to provide written informed consent
Chronic genotype 1 or 4 HCV infection
Normal ECG
Negative serum pregnancy test for female subjects
Male subjects and female subjects of childbearing potential must agree to use contraception
Able to comply with the dosing instructions for study drug and able to complete the study schedule of assessments, including all required post treatment visits
You may not be if
Serious or active medical or psychiatric illness
HIV or hepatitis B viral (HBV) infection
Stomach disorder that could interfere with the absorption of the study drug
Treated with an anti-HCV medication in the last 30 days
Any prior exposure to an HCV nonstructural protein (NS)5a-specific inhibitor
Use of human granulocyte-macrophage colony-stimulating factor (GM-CSF), epoetin alfa or other therapeutic hematopoietic agents within 2 weeks of screening
History of clinically significant medical condition associated with other chronic liver disease
Active spontaneous bacterial peritonitis at screening
Females who are breastfeeding
Infection requiring systemic antibiotics
Participated in a clinical study with an investigational drug or biologic within the last 30 days
Active or history (last 6 months) of drug or alcohol abuse
History of organ transplant other than liver or kidney
Clareo Health | Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant
